GC
REGN icon

GFG Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

GFG Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$1.05K – 283
2025
Q2 		$1.05K Buy
+2
New +$1.12K ﹤0.01% 350
2022
Q1 		– Sell
-595
Closed -$376K – 164
2021
Q4 		$376K Buy
595
+32
+6% +$19.7K 0.11% 95
2021
Q3 		$341K Buy
563
+7
+1% +$4.35K 0.11% 89
2021
Q2 		$311K Buy
556
+10
+2% +$5.07K 0.09% 94
2021
Q1 		$258K Sell
546
-580
-52% -$282K 0.09% 94
2020
Q4 		$544K Buy
1,126
+21
+2% +$11.3K 0.18% 69
2020
Q3 		$619K Sell
1,105
-8
-0.7% -$4.85K 0.24% 58
2020
Q2 		$694K Buy
1,113
+38
+4% +$21.6K 0.3% 49
2020
Q1 		$525K Buy
1,075
+8
+0.7% +$3.3K 0.27% 45
2019
Q4 		$401K Buy
+1,067
New +$359K 0.17% 56

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GFG Capital's REGN Position: Q3 2025 in Review

GFG Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 2 shares — an estimated $1.05K sold.

GFG Capital first reported a position in REGN in Q4 2019 and held it in 10 quarters. The position peaked at $694K in Q2 2020. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • GFG Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • GFG Capital sold 2 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.05K.
  • GFG Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 10 quarters.
  • GFG Capital's Regeneron Pharmaceuticals position peaked at $694K in Q2 2020.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.